Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs

Virginie Baylot,Thi Khanh Le,David Taïeb,Palma Rocchi,Laurence Colleaux

DOI: https://doi.org/10.1038/s42003-024-06121-9

IF: 6.548

2024-04-24

Communications Biology

Abstract:Rare diseases (RD) affect a small number of people compared to the general population and are mostly genetic in origin. The first clinical signs often appear at birth or in childhood, and patients endure high levels of pain and progressive loss of autonomy frequently associated with short life expectancy. Until recently, the low prevalence of RD and the gatekeeping delay in their diagnosis have long hampered research. The era of nucleic acid (NA)-based therapies has revolutionized the landscape of RD treatment and new hopes arise with the perspectives of disease-modifying drugs development as some NA-based therapies are now entering the clinical stage. Herein, we review NA-based drugs that were approved and are currently under investigation for the treatment of RD. We also discuss the recent structural improvements of NA-based therapeutics and delivery system, which overcome the main limitations in their market expansion and the current approaches that are developed to address the endosomal escape issue. We finally open the discussion on the ethical and societal issues that raise this new technology in terms of regulatory approval and sustainability of production.

biology

What problem does this paper attempt to address?

The paper primarily explores the application and development of nucleic acid (NA)-based drugs in the treatment of rare genetic diseases. Specifically, the article covers the following aspects:

1. **Background Introduction**: Rare Diseases (RD) affect a relatively small population, and most have a genetic basis. The clinical manifestations of these diseases usually appear at birth or during childhood, accompanied by long-term suffering, decreased quality of life, and shorter life expectancy.

2. **Therapeutic Progress**: In recent years, nucleic acid-based therapies have brought revolutionary changes to the treatment of rare genetic diseases, especially as some NA-based drugs have entered clinical stages, bringing new hope to patients.

3. **Approved and Investigational NA-based Drugs**: The paper reviews NA-based drugs that have been approved for the treatment of rare genetic diseases, as well as those currently under investigation. These drugs include gene replacement therapy, small interfering RNA (siRNA) therapy, and antisense oligonucleotide (ASO) therapy.

4. **Structural Improvements and Delivery Systems**: The latest structural improvements of NA-based drugs and their delivery systems are discussed. These improvements help overcome major limitations in market expansion, and current solutions to the issue of endosomal escape are introduced.

5. **Ethical and Social Issues**: Finally, the paper discusses some ethical and social issues raised by NA-based drug technology in terms of regulatory approval and production sustainability.

In summary, this paper aims to provide a comprehensive overview of the latest advancements, challenges, and future directions of nucleic acid-based drugs in the treatment of rare genetic diseases.